Medicine Advances最新文献

{"title":"Generative Pre-Trained Transformer 4 in healthcare: Challenges, opportunities, and recommendations","authors":"Hassam Ali","doi":"10.1002/med4.21","DOIUrl":"https://doi.org/10.1002/med4.21","url":null,"abstract":"<p>GPT-4's advanced natural language processing capabilities can revolutionize patient education and clinical decision-making in healthcare, providing personalized and easily accessible content. Despite its potential, GPT-4's integration into healthcare raises important ethical and legal questions, particularly around data security, privacy, and transparency. To fully utilize GPT-4 in healthcare, further research, comprehensive regulations, and AI training in medical curricula are recommended.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.21","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50129978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric investigation of undergraduate pharmacy education since the millennium via web of science","authors":"Zhengwei Huang,&nbsp;Rui Luo,&nbsp;Si Xiong,&nbsp;Chuanbin Wu,&nbsp;Xin Pan","doi":"10.1002/med4.15","DOIUrl":"https://doi.org/10.1002/med4.15","url":null,"abstract":"<p>The status quo of the current knowledge in pharmacy undergraduate education was figured out by bibliometric studies. Based on the current research hotspots, we proposed several suggestions for future directions.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50139341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optical coherence tomography angiography features of retinal artery occlusion before and after intra-arterial thrombolysis","authors":"Qiaowei Wu,&nbsp;Yongyi Niu,&nbsp;Daiyu Chen,&nbsp;Hongbin Lin,&nbsp;Mingkui Tan,&nbsp;Yijun Hu,&nbsp;Honghua Yu,&nbsp;Anyi Liang","doi":"10.1002/med4.14","DOIUrl":"https://doi.org/10.1002/med4.14","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To evaluate the ability of optical coherence tomography angiography (OCTA) to quantitatively assess the effectiveness of intra-arterial thrombolysis (IAT) surgery for the treatment of retinal artery occlusion (RAO).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a prospective observational study. Patients diagnosed with RAO who received IAT were enrolled. All participants underwent comprehensive ophthalmologic examinations and OCTA scans. The best-corrected visual acuity (BCVA), vascular densities (VDs) of the superficial capillary plexus (SCP), deep capillary plexus (DCP), radial peripapillary capillaries, and central retinal thickness (CRT) were recorded. The above parameters were compared between RAO eyes and the fellow healthy eyes before and after IAT. Correlations between the BCVA and OCTA parameters in RAO eyes were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-four eyes from 34 consecutive RAO patients with a mean age of 51.0 ± 12.9 years were enrolled. There was a considerable decrease of VDs in the SCP, DCP, and radial peripapillary capillaries in all RAO eyes (all <i>p</i> &lt; 0.001). Compared with contralateral normal eyes, CRT was significantly increased in RAO eyes (<i>p</i> &lt; 0.001). The SCP and DCP VDs were significantly improved after IAT surgery (<i>p</i> = 0.010 and 0.014, respectively). BCVA in logMAR unit was negatively correlated with the DCP VD (<i>r</i> = −0.664, <i>p</i> = 0.010) and positively correlated with CRT (<i>r</i> = 0.597, <i>p</i> = 0.024) after surgery, but not significantly correlated with VDs or CRT before surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Macular and peripapillary VDs of the retina detected by OCTA were greatly decreased in RAO eyes and improved after IAT treatment. OCTA is capable of quantifying VDs in separate retinal layers non-invasively, conveniently, efficiently, and precisely.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50156143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus on treatment for stage III non-small cell lung cancer","authors":"Yi-Long Wu,&nbsp;Shun Lu,&nbsp;Qinghua Zhou,&nbsp;Li Zhang,&nbsp;Ying Cheng,&nbsp;Jie Wang,&nbsp;Buhai Wang,&nbsp;Chengping Hu,&nbsp;Lizhu Lin,&nbsp;Wenzhao Zhong,&nbsp;Yong Song,&nbsp;Nong Yang,&nbsp;Xiaorong Dong,&nbsp;Jian Zhao,&nbsp;Haihong Yang,&nbsp;Hui Guo,&nbsp;Xiaolong Yan,&nbsp;Hongxu Liu,&nbsp;Rui Ma,&nbsp;Jie Lin,&nbsp;Siyang Liu,&nbsp;Chun Chen,&nbsp;Lifeng Wang,&nbsp;Chengzhi Zhou,&nbsp;Ming Zhou,&nbsp;Fang Wu,&nbsp;Xue-Ning Yang,&nbsp;Yingying Du,&nbsp;Yu Yao,&nbsp;Yang Shao,&nbsp;Shaodong Hong,&nbsp;Jiuwei Cui,&nbsp;Xueping Quan,&nbsp;Rongrong Chen,&nbsp;Jiayan Wu,&nbsp;Jiatao Zhang,&nbsp;Jianya Zhou,&nbsp;Binchao Wang,&nbsp;Chao Cheng,&nbsp;Huijuan Wang,&nbsp;Jingjing Liu,&nbsp;Lin Wu,&nbsp;Yan Huang,&nbsp;Yukun Kuang,&nbsp;Yongchang Zhang,&nbsp;Jia Hu,&nbsp;Jinji Yang,&nbsp;Weineng Feng,&nbsp;Wenmei Su,&nbsp;Yun Fan,&nbsp;Fan Yang,&nbsp;Ming Chen,&nbsp;Kejing Tang,&nbsp;Yi Pan,&nbsp;Peng Shen,&nbsp;Anwen Liu,&nbsp;Haibo Zhang,&nbsp;Wenhua Liang,&nbsp;Qing Zhou,&nbsp;Zhiyong Ma,&nbsp;Xiuyu Cai,&nbsp;Hui Liu,&nbsp;Longfei Chen,&nbsp;Shaokun Chuai,&nbsp;Jianzhen Shan,&nbsp;Yanfang Zheng,&nbsp;Changxuan You,&nbsp;Xiaoxia Zhu,&nbsp;Li Li,&nbsp;Tongmei Zhang,&nbsp;Haiyan Tu,&nbsp;Wurong Lin,&nbsp;Xuchao Zhang,&nbsp;Penghui Zhou,&nbsp;Zunfu Ke,&nbsp;Huiying Liang","doi":"10.1002/med4.7","DOIUrl":"https://doi.org/10.1002/med4.7","url":null,"abstract":"<p>Stage III non-small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation with a multiple disciplinary team, which allows the development of a proposal for clinical diagnosis and treatment. In this consensus, stage III NSCLC is divided into two types (operable and inoperable) according to different clinical conditions. Resectable NSCLC is further subdivided into two conditions (with or without driver genes). For each clinical scenario, this consensus emphasizes that the foundation of any medical decisions regarding the optimal diagnostic or therapy procedure is scientific evidence from clinical research. Finally, based on the level of evidence and strength of recommendations, this consensus provides recommendations for the management of stage III NSCLC from six perspectives. The objective of this consensus is to help clinicians choose the best treatment and promote the standardization of stage III NSCLC diagnosis and treatment in China.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretation of expert consensus on treatment for stage III non-small cell lung cancer","authors":"Weichi Luo,&nbsp;Riwei Zhong,&nbsp;Mingyi Yang,&nbsp;Qing Zhou","doi":"10.1002/med4.5","DOIUrl":"https://doi.org/10.1002/med4.5","url":null,"abstract":"<p>Stage III non-small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Currently, it is considered that both staging and optimal treatment of stage III NSCLC require the joint work of a multidisciplinary team (MDT) of expert physicians within the tumor committee. With the advent of precision therapy, targeted therapy and immunotherapy provide more novel options for patients with stage III NSCLC. However, the management of stage III NSCLC remains complex and controversial, with a myriad of potentially feasible options. At present, the management of stage III NSCLC does not satisfy medical needs, and consistent progress and breakthroughs are urgently needed in standardized diagnosis and treatment strategies. Moreover, the unique demographics of Chinese NSCLC pose further challenges when applying clinical trial data into clinical practice. This includes differences in smoking rates, prevalence of oncogenic driver mutations, and access to health care resources [<span>1, 2</span>]. In view of the above situation, after in-depth communications and discussions, experts on lung cancer clinical research, transformational research, and basic research achieved consensuses about the multidisciplinary comprehensive treatment and biomarkers for resectable and unresectable stage III NSCLC at the 19th lung cancer summit and issued Expert Consensus on Treatment for Stage III Non-Small Cell Lung Cancer on June 15, 2022 [<span>3</span>].</p><p>The consensus provides recommendations in the following six respects: (1) Redefining the definition of “resectability”; (2) adjuvant targeted therapy for stage III NSCLC patients; (3) adjuvant immunotherapy for wild type stage III NSCLC; (4) selection of neoadjuvant or adjuvant therapy for stage III NSCLC patients; (5) treatment options for unresectable stage III NSCLC patients; and (6) translational research on molecular residual disease (MRD). Meanwhile, the level of evidence and strength of recommendations for this consensus are described in an easy-to-understand way and in line with international standards.</p><p>The consensus recommends adjuvant immunotherapy for driver mutation-negative patients with stage III NSCLC in line with NCCN guidelines, which is different in ASCO and ESMO guidelines [<span>4-6</span>]. The consensus recommends that adjuvant immunotherapy should be administered after the completion of postoperative chemotherapy and should be restricted to PD-L1-positive patients, preferably for patients with PD-L1 &gt; 50%. Stage III NSCLC patients who refuse adjuvant chemotherapy but have PD-L1 &gt; 50% can consider receiving adjuvant immunotherapy.</p><p>The previous guidelines only recommended immune checkpoint inhibitor (ICI) consolidation therapy after concurrent chemoradiotherapy for patients with stage III NSCLC. With the publication of GEMSTONE-301 trial, the consensus recommends ICI consolidation therapy not only after concurrent chemoradiotherapy but also after sequent","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA sequencing reveals distinct immune cell subsets in phalangeal and soft-tissue recurrence of giant cell tumor of bone","authors":"Meiling Yang,&nbsp;Fen Wang,&nbsp;Huishan Liang,&nbsp;Genxin Ji,&nbsp;Yating Lian,&nbsp;Changye Zou,&nbsp;Wei Zhao","doi":"10.1002/med4.10","DOIUrl":"https://doi.org/10.1002/med4.10","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Giant cell tumor of the bone (GCTB), an intermediate locally aggressive neoplasm that frequently involves the epiphyseal region of the long bones. GCTB of the distal phalanx and soft-tissue recurrences are extremely rare. Little is known about the cellular and molecular differences between GCTB of the long bones and rare sites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We employed single-cell RNA sequencing to elucidate the transcriptional profiles of 28,992 cells originating from patients afflicted with GCTB in the femur, distal phalanx, and soft-tissue relapse. To confirm the critical findings, we subjected the paraffin sections of GCTB to immunohistochemical staining.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our study revealed that GCTBs in rare sites display distinct immune subtypes and antigen presentation gene signatures. We observed minimal lymphocyte infiltration in GCTBs of the phalanx. Further analyses demonstrated that the transforming growth factor-β pathway and profibrotic proteins were significantly upregulated in phalanx lesions. In contrast, GCTB cells from soft-tissue recurrence exhibited discernible chondrocyte characteristics but presented lower antigen-presenting ability compared to those from femur lesions. Notably, we identified an immunosuppressive subset of mast cells in the soft-tissue recurrence. The secretion of proangiogenic and immunosuppressive factors from these mast cells suggests their potential role in the formation of vascular-rich and immunosuppressive niches in recurrent lesions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Collectively, this study broadens our comprehension of the gene expression patterns observed in infrequent location GCTBs and furnishes a repository of information for illuminating promising therapeutic targets for rare GCTBs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global prevalence of Staphylococcus aureus in food products and its relationship with the occurrence and development of diabetes mellitus","authors":"Tingting Liang,&nbsp;Zhuang Liang,&nbsp;Shi Wu,&nbsp;Yu Ding,&nbsp;Qingping Wu,&nbsp;Bing Gu","doi":"10.1002/med4.6","DOIUrl":"https://doi.org/10.1002/med4.6","url":null,"abstract":"<p>The worldwide distribution of <i>Staphylococcus aureus</i> across food types is an important food safety concern. This study aimed to estimate the prevalence of <i>S. aureus</i> in food products and its relationship with the occurrence and development of diabetes mellitus. A total of 55 articles were included. The pooled prevalence of <i>S. aureus</i> was 30.2%. The highest prevalence of <i>S. aureus</i> was observed in cereals, followed by meat and bean products, and the lowest in confectionery, egg products, and vegetables. The prevalence in dairy and seafood products was similar. Combinations of culture and molecular methods have been used for <i>S. aureus</i> detection. Furthermore, the prevalence of <i>S. aureus</i> in developed countries (Europe and North America) was higher than that in developing countries (Asia and Africa). In addition, the prevalence was higher in the provinces of Xinjiang and Shaanxi than that in Sichuan and Shandong in China, which may be due to the difference in climate and dietary habits. The results revealed that food type, bacterial detection methods, and location can influence the prevalence of <i>S. aureus</i> contamination. Resistance rates to preferred antibiotics against <i>S. aureus</i> were the highest for cephradine, polymyxin B, and penicillin at 82.9%, 82.0%, and 81.3%, respectively. In addition, 17 studies were system reviewed that the <i>S. aureus</i> infections are closely associated with the development of diabetes, and the treatment of probiotic, prebiotic, FMT, and bacteriophage can prevent and control <i>S. aureus</i> infections. This review emphasizes the high prevalence of <i>S. aureus</i> contamination in food, suggesting a potential diabetic infection risk and importance of observing principles of food safety and hygiene to reduce <i>S. aureus</i>.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50140349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular residual disease: A new clue for individualized approach in non-small cell lung cancer","authors":"Jia-Tao Zhang,&nbsp;Wen-Zhao Zhong,&nbsp;Yi-Long Wu","doi":"10.1002/med4.11","DOIUrl":"https://doi.org/10.1002/med4.11","url":null,"abstract":"<p>The prognostic value of molecular residual disease (MRD) in non-small cell lung cancer (NSCLC) cases using high-depth circulating tumor DNA (ctDNA) sequencing has been well documented. The utility of MRD to direct individualized therapy has increasingly emerged in the clinical trial design of solid tumors, such as escalation or de-escalation of adjuvant therapy based on MRD. And the efficiency of MRD assay is a key determinant to the success of clinical trials, especially the limitation of detection and predictive value. Here, we review the progress made in evaluating the clinical validity of ctDNA-MRD test and provide insight into exploiting these developments to future clinical scenarios for improving the individualized therapy of NSCLC.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50140350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The inauguration of Medicine Advances","authors":"Xueqing Yu","doi":"10.1002/med4.13","DOIUrl":"https://doi.org/10.1002/med4.13","url":null,"abstract":"<p>Over the years, the field of medicine has made important strides in improving the quality of life for millions of people around the world. From groundbreaking treatments for cancer and other diseases to new technologies revolutionizing how we diagnose and treat patients, the past few decades have witnessed an explosion of medical innovation. However, there remains much to be done. The world is facing unprecedented challenges, from global pandemics to chronic diseases, which have profound impacts on individuals, families, and communities. The only way to overcome these challenges is by harnessing the power of science and innovation, which is where <i>Medicine Advances</i> comes in. As its name suggests, this new journal is dedicated to advancing the field of medicine by publishing cutting-edge research, ranging from basic science to clinical practice. Our mission is to provide a platform for the dissemination of knowledge to drive progress and improve patient outcomes.</p><p><i>Medicine Advances</i> has been created to bring together researchers, health care professionals, policymakers, and industry leaders to share their knowledge and expertise. Through this journal, we hope to foster collaboration, exchange ideas, and inspire new approaches for tackling the most pressing health issues of our time. We will explore a wide range of topics, including latest developments in precision medicine, the role of artificial intelligence and machine learning in health care, and the impact of genomics on disease prevention and treatment. We will also discuss challenges and opportunities in global health and the importance of equity and access to health care for all.</p><p><i>Medicine Advances</i> is an open-access general medical journal with a focus on new technologies, new methods, and new products in the full life cycle of diseases, including development and progression, screening and early warning, diagnosis and classification, treatment and intervention, and prognosis, as well as exploration and innovation in interdisciplinary medical research, including but not limited to new drug development and artificial intelligence applications. <i>Medicine Advances</i> aims to provide a platform for researchers, scholars, and practitioners in health care to communicate and share their scientific findings and innovations. The journal is committed to promoting new medical theories, exchanging new clinical technologies, presenting new medical products, and accelerating the pace of medical development. This journal is dedicated to publishing high-quality original research articles, reviews, survey articles, case reports, editorials, and short communications.</p><p>As we launch this journal, I want to express my gratitude to the many researchers, clinicians, and other health-care professionals who have contributed to its creation. I also want to thank the editorial board and staff who will no doubt work tirelessly to ensure that <i>Medicine Advances</i> achieves its ","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50140323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between birth weight and the risk of chronic kidney disease in men and women: Findings from a large prospective cohort study","authors":"Lingyan Dai,&nbsp;Juncheng Zhuang,&nbsp;Li Fan,&nbsp;Xia Zou,&nbsp;Kei Hang Katie Chan,&nbsp;Xueqing Yu,&nbsp;Jie Li","doi":"10.1002/med4.8","DOIUrl":"https://doi.org/10.1002/med4.8","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The sex-specific associations between birth weight and the risk of chronic kidney disease (CKD) later in life remain controversial. This study aimed to examine the shape of the relationship between birth weight and the risk of CKD in men and women.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 277,252 participants free of CKD at baseline from the United Kingdom Biobank (UKB) prospective cohort were included in the analysis. Cox proportional hazard regression model was used to estimate the association between birth weight and the risk of incident CKD with adjustment for potential confounders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During a median follow-up of 11.9 years, we identified 13,030 (4.7%) CKD cases. Compared with normal birth weight (2.5–4.0 kg), low birth weight (LBW, &lt;2.5 kg) was associated with an 11% higher risk of CKD in men (adjusted hazard ratio [HR]: 1.11 [95% CI 1.01–1.21]) and a 27% higher risk of CKD in women (HR: 1.27 [1.19–1.36]) (<i>p</i> for interaction = 0.02). High birth weight (HBW, &gt;4.0 kg) was associated with an 11% lower risk of CKD (HR: 0.89 [0.83–0.95]) in men but not in women (HR: 0.96 [0.89–1.04]) (<i>p</i> for interaction = 0.13). Furthermore, the LBW-CKD association was stronger in obese (HR: 1.28 [1.18–1.39]) than in nonobese participants (HR: 1.16 [1.09–1.24], <i>p</i> for interaction = 0.03).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We found an L-shaped relationship between birth weight and the risk of CKD in women but a linear shape in men. The LBW-CKD association was mitigated to some extent by maintaining healthy body weight in adulthood. Our findings support the notion that the CKD risk should be managed from a lifecycle perspective.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50140322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}